CY1124637T1 - Αυξημενη οξινη αλφα-γαυκοσιδαση για την θεραπευτικη αγωγη της νοσου ρομρe - Google Patents
Αυξημενη οξινη αλφα-γαυκοσιδαση για την θεραπευτικη αγωγη της νοσου ρομρeInfo
- Publication number
- CY1124637T1 CY1124637T1 CY20211100705T CY211100705T CY1124637T1 CY 1124637 T1 CY1124637 T1 CY 1124637T1 CY 20211100705 T CY20211100705 T CY 20211100705T CY 211100705 T CY211100705 T CY 211100705T CY 1124637 T1 CY1124637 T1 CY 1124637T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- romre
- gaucosidase
- acid alpha
- glucosidase
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 3
- 102000045921 human GAA Human genes 0.000 abstract 3
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 abstract 1
- 229960001512 miglustat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Παρέχεται μια μέθοδος θεραπευτικής αγωγής της νόσου Pompe η οποία περιλαμβάνει χορήγηση ανασυνδυασμένης ανθρώπινης όξινης α-γλυκοσιδάσης που έχει βέλτιστη γλυκοζυλίωση με υπολείμματα 6-φωσφορικής μαννόζης σε συνδυασμό με μια ποσότητα μιγλουστάτης αποτελεσματική για την μεγιστοποίηση της πρόσληψης ανασυνδυασμένης ανθρώπινης όξινης α-γλυκοσιδάσης, ενώ ελαχιστοποιείται η αναστολή της ενζυματικής δραστικότητας της ανασυνδυασμένης ανθρώπινης όξινης α-γλυκοσιδάσης.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272890P | 2015-12-30 | 2015-12-30 | |
| US201662300479P | 2016-02-26 | 2016-02-26 | |
| US201662315412P | 2016-03-30 | 2016-03-30 | |
| US201662402454P | 2016-09-30 | 2016-09-30 | |
| US201662428867P | 2016-12-01 | 2016-12-01 | |
| US201662431791P | 2016-12-08 | 2016-12-08 | |
| PCT/US2016/069243 WO2017117407A1 (en) | 2015-12-30 | 2016-12-29 | Augmented acid alpha-glucosidase for the treatment of pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124637T1 true CY1124637T1 (el) | 2022-07-22 |
Family
ID=60186557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100705T CY1124637T1 (el) | 2015-12-30 | 2021-08-06 | Αυξημενη οξινη αλφα-γαυκοσιδαση για την θεραπευτικη αγωγη της νοσου ρομρe |
Country Status (15)
| Country | Link |
|---|---|
| EP (3) | EP3957320B1 (el) |
| CN (1) | CN108472340A (el) |
| CY (1) | CY1124637T1 (el) |
| DK (2) | DK3957320T5 (el) |
| ES (2) | ES2965190T3 (el) |
| FI (1) | FI3957320T3 (el) |
| HK (1) | HK1253014A1 (el) |
| HR (2) | HRP20231465T1 (el) |
| HU (2) | HUE054733T2 (el) |
| LT (2) | LT3397273T (el) |
| PL (2) | PL3397273T3 (el) |
| PT (2) | PT3397273T (el) |
| RS (2) | RS64843B1 (el) |
| SI (2) | SI3397273T1 (el) |
| TW (2) | TWI753874B (el) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| CA2814774C (en) | 2003-01-31 | 2016-03-22 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
| ATE465250T1 (de) * | 2004-02-10 | 2010-05-15 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| PT3470077T (pt) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| AU2010254092B2 (en) * | 2009-05-26 | 2015-11-12 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| PT2844279T (pt) | 2012-05-03 | 2021-03-11 | Amicus Therapeutics Inc | Esquema posológico para o tratamento da doença de pompe |
| WO2014014938A1 (en) | 2012-07-17 | 2014-01-23 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| PT3201320T (pt) * | 2014-09-30 | 2024-01-12 | Amicus Therapeutics Inc | Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados |
-
2016
- 2016-12-29 DK DK21174249.9T patent/DK3957320T5/da active
- 2016-12-29 RS RS20231076A patent/RS64843B1/sr unknown
- 2016-12-29 PL PL16826898T patent/PL3397273T3/pl unknown
- 2016-12-29 HU HUE16826898A patent/HUE054733T2/hu unknown
- 2016-12-29 HR HRP20231465TT patent/HRP20231465T1/hr unknown
- 2016-12-29 RS RS20210984A patent/RS62212B1/sr unknown
- 2016-12-29 EP EP21174249.9A patent/EP3957320B1/en active Active
- 2016-12-29 PL PL21174249.9T patent/PL3957320T3/pl unknown
- 2016-12-29 ES ES21174249T patent/ES2965190T3/es active Active
- 2016-12-29 CN CN201680077801.5A patent/CN108472340A/zh active Pending
- 2016-12-29 FI FIEP21174249.9T patent/FI3957320T3/fi active
- 2016-12-29 PT PT168268985T patent/PT3397273T/pt unknown
- 2016-12-29 DK DK16826898.5T patent/DK3397273T3/da active
- 2016-12-29 EP EP23188938.7A patent/EP4285902A3/en active Pending
- 2016-12-29 SI SI201631258T patent/SI3397273T1/sl unknown
- 2016-12-29 LT LTEP16826898.5T patent/LT3397273T/lt unknown
- 2016-12-29 LT LTEP21174249.9T patent/LT3957320T/lt unknown
- 2016-12-29 SI SI201631766T patent/SI3957320T1/sl unknown
- 2016-12-29 PT PT211742499T patent/PT3957320T/pt unknown
- 2016-12-29 HU HUE21174249A patent/HUE064049T2/hu unknown
- 2016-12-29 ES ES16826898T patent/ES2883844T3/es active Active
- 2016-12-29 EP EP16826898.5A patent/EP3397273B1/en active Active
- 2016-12-30 TW TW105144116A patent/TWI753874B/zh active
- 2016-12-30 TW TW111105262A patent/TWI849380B/zh active
-
2018
- 2018-09-27 HK HK18112390.1A patent/HK1253014A1/zh unknown
-
2021
- 2021-06-07 HR HRP20210894TT patent/HRP20210894T1/hr unknown
- 2021-08-06 CY CY20211100705T patent/CY1124637T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3397273T (lt) | 2021-06-25 |
| ES2883844T3 (es) | 2021-12-09 |
| EP3957320B1 (en) | 2023-08-23 |
| EP3397273B1 (en) | 2021-05-19 |
| EP4285902A2 (en) | 2023-12-06 |
| EP3957320A1 (en) | 2022-02-23 |
| LT3957320T (lt) | 2023-12-11 |
| SI3397273T1 (sl) | 2021-11-30 |
| DK3957320T5 (da) | 2024-08-05 |
| PL3957320T3 (pl) | 2024-02-19 |
| HUE054733T2 (hu) | 2021-09-28 |
| TWI849380B (zh) | 2024-07-21 |
| HK1253014A1 (zh) | 2019-06-06 |
| DK3957320T3 (da) | 2023-11-27 |
| DK3397273T3 (da) | 2021-08-09 |
| TWI753874B (zh) | 2022-02-01 |
| HUE064049T2 (hu) | 2024-02-28 |
| CN108472340A (zh) | 2018-08-31 |
| PT3397273T (pt) | 2021-08-09 |
| EP3397273A1 (en) | 2018-11-07 |
| HRP20210894T1 (hr) | 2021-07-23 |
| SI3957320T1 (sl) | 2024-01-31 |
| PT3957320T (pt) | 2023-11-23 |
| RS62212B1 (sr) | 2021-09-30 |
| EP4285902A3 (en) | 2024-02-21 |
| FI3957320T3 (fi) | 2023-11-23 |
| PL3397273T3 (pl) | 2021-12-06 |
| ES2965190T3 (es) | 2024-04-11 |
| TW202245831A (zh) | 2022-12-01 |
| TW201726163A (zh) | 2017-08-01 |
| HRP20231465T1 (hr) | 2024-03-01 |
| RS64843B1 (sr) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CO2018007680A2 (es) | Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo | |
| MX2018011833A (es) | Tratamiento para la debilidad muscular con fosfatasas alcalinas. | |
| BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
| BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
| ZA201506093B (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
| EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
| EA201301018A1 (ru) | Режимы дозирования для лечения болезни фабри | |
| MX2018008709A (es) | Uso terapeutico de inhibidores de activacion o estimulacion de celulas t. | |
| MX2015005252A (es) | Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1. | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| BR112016018170A2 (pt) | métodos para tratar doença de alzheimer | |
| BR112018009361A8 (pt) | composições e métodos para o tratamento de doenças autoimunes e de câncer | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
| MX2017002948A (es) | Métodos de tratamiento para la sarcoidosis pulmonar. | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX2017001898A (es) | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| CY1124637T1 (el) | Αυξημενη οξινη αλφα-γαυκοσιδαση για την θεραπευτικη αγωγη της νοσου ρομρe | |
| EA201500765A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| IN2014MN01806A (el) |